Malate dehydrogenase 1B (MDH1B)

Malate dehydrogenase 1B is a predicted NAD⁺-dependent cytosolic enzyme involved in the interconversion of malate and oxaloacetate in the tricarboxylic acid (TCA) cycle, contributing to cellular energy production and metabolic processes[4][5]. Structurally, it shares high similarity with the canonical malate dehydrogenase 1 (MDH1), with conservation of catalytic residues typical of the family, including the Rossmann fold and key substrate-binding motifs[1][2]. The enzyme is primarily intracellular, with expression noted in various tissues, and alterations or dysfunction may be implicated in rare hereditary encephalopathies, Bloom syndrome, and possibly cancer[4][6]. While drugs directly targeting MDH1B have not been described, the enzyme is considered a promising emerging target for metabolic intervention in oncology; selective inhibition could theoretically impair metabolic flux critical for cell proliferation[1][2][5].

Other names

MDH1BPutative malate dehydrogenase 1BFLJ25341RP11-95H11Malate dehydrogenase 1B, NAD (soluble)

Inhibition of NAD⁺/NADH-dependent malate oxidation (proposed for similar MDH1 isoenzymes, with selectivity possible due to structural differences; may block TCA cycle flux and energy metabolism in cancer cells)